Advanced Hip Replacement Solutions from Zimmer Offer Once In A Lifetime Technology

Aug 22, 2014

(WARSAW, IN) August 22, 2014-Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today its launch of the nationwide *Forever Hip*™ campaign in support of what the Company believes to be the first hip replacement technology to demonstrate a lifetime of wear performance based on new material advancements and unprecedented testing.

"Hip replacement is being performed on younger patients who are more active than ever. They need solutions capable of providing improved long-term performance in order to reclaim their mobility and get back to doing the things they enjoy most, being forever hip," said Matt Monaghan, Senior Vice President of Global Hips and Reconstructive Research for Zimmer. "Wear-related complications are one of the most jeopardizing factors for long-term implant success. Zimmer continues to drive innovation in this area, to meet and exceed younger and more active patient demands."

In ongoing laboratory testing that has surpassed simulation of more than 34 years of walking activity, Zimmer's *Vivacit-E*® Vitamin E highly crosslinked polyethylene (HXPE) liners continue to demonstrate ultra-low long-term wear properties under typical conditions and reduce one of the leading barriers to long-term hip replacement success. Based on this extensive research, *Vivacit-E* Vitamin E HXPE is now the only hip replacement technology laboratory tested to mimic the number of walking steps a patient will typically take during their lifetime following hip replacement surgery.*

"With the advanced wear resistance of Zimmer's proprietary Vivacit-E bearing surface, surgeons can now provide a once in a lifetime hip replacement technology for their most demanding patients," added Mr. Monaghan. "This industry leading technology can potentially help patients avoid pain and lost time due to re-operation, as well as lessen the economic burdens that can strain patients and hospitals."

Each year, it is estimated that more than 330,000 Americans have experienced relief and restored mobility through total hip replacement. As an increasingly large number of these patients receive hip replacements at a younger age, *Vivacit-E* Vitamin E HXPE can be combined with Zimmer's other

premium technologies such as *Trabecular Metal*™ Material and *BIOLOX*® delta Ceramic to create a high-demand construct for the younger and more active patient.

For more information on Zimmer's *Vivacit-E* Vitamin E Technology, visit www.ForeverHip.com.

*Zimmer's *Vivacit-E* Vitamin E HXPE has been evaluated for 80 million walking cycles of simulated wear testing in ongoing laboratory testing. Results assume a hip replacement patient will have a life expectancy of 34 years following hip replacement surgery and walk up to 2.2 million steps per year. The results of laboratory testing have not been proven to predict actual performance in people.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2013 sales were approximately $4.6 billion. The Company is supported by the efforts of more than 9,000 employees worldwide. More information about Zimmer is available at *www.zimmer.com*.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of Zimmer's management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to: future test results or patient experiences being inconsistent with test findings to date; actions of regulatory bodies or other governmental authorities; changes in laws and regulations; competitive developments; and other risks and uncertainties described in Zimmer's periodic reports filed with the U.S. Securities and Exchange Commission. Zimmer disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in Zimmer's periodic reports. Readers of this communication are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.